Latest News

Toronto, Canada - J. Rettenmaier & Söhne (JRS) is pleased to announce the opening of a new Rettenmaier Sales Company – Rettenmaier Canada Inc. in the Greater Toronto Area (GTA) Canada.

JRS PHARMA is pleased to announce that its Star-Tech & JRS Specialty Products excipients manufacturing site in Chongqing, China, has been awarded EXCiPACT certification.

JRS PHARMA has announced the upcoming grand opening of a new laboratory located at their Diadema, Brazil location. The lab is scheduled to be opened during JRS PHARMA’s Latin America Technical Seminar on June 26-27, 2017.

JRS PHARMA has announced the worldwide release of the Povidone Family product line, the latest addition to their excipients portfolio. This product line consists of three products: VIVAPHARM® PVP (Povidone), VIVAPHARM® PVP/VA 64 (Copovidone), and VIVAPHARM® PVPP (Crospovidone).

JRS PHARMA, headquartered in Germany, has entered into a joint venture agreement with SSP, headquartered in Chongqing, China, for the commercialization of povidone products. The new JV company is Star-Tech & JRS Specialty Products.

JRS PHARMA products can now be purchased direct in India. All business has been transferred from S. Zhaveri Pharmakem Pvt. Ltd. to Rettenmaier India Pvt. Ltd., a wholly owned subsidiary of the JRS Group ( J. RETTENMAIER & Söhne)

We are excited to announce that Michael Hampel has been named the new CEO of our North American Pharma division.

JRS Pharma continues to expand and advance our manufacturing capabilities. We are pleased to share that the construction of our new manufacturing facility for dextrates products will soon be complete.